Newsroom

Sight Sciences Presents Additional Results of OLYMPIA Study Demonstrating Successful Treatment of Signs and Symptoms of Dry Eye Disease using TearCare

Data presented at the Women in Ophthalmology 2020 Virtual Summer Symposium show the novel eyelid procedure successfully achieved clinically meaningful reductions in signs and symptoms of dry eye

read more +
Sight Sciences Announces Positive Clinical Results from Randomized, Controlled Trial of TearCare for the Treatment of Dry Eye Disease

Data Presented at the ASCRS Virtual Meeting Shows the Novel Eyelid Procedure Met All Dry Eye Signs and Symptoms Endpoints

read more +
First Subject Enrolled in large, multi-center pivotal trial to confirm safety and efficacy of TearCare® in the treatment of signs and symptoms of Dry Eye disease

Sight Sciences, Inc., a growth-stage medical device company transforming the two fastest growing segments in ophthalmology and optometry, glaucoma and dry eye, today announced the first subject has been enrolled...

read more +
Sight Sciences Announces Official Launches of TearCare® and the Enhanced, Next Generation OMNI® System

New Dry Eye and MIGS Entrants will be Prominently Featured in Product Demonstrations and Events at Upcoming Industry Shows MENLO PARK, Calif. – Sight Sciences, Inc., a growth-stage medical device company...

read more +
Retreatment With A Single TearCare® Treatment Continues To Provide Relief For Patients With Dry Eye Disease

A new, single center, prospective clinical study published in the January issue of Clinical Ophthalmology provides preliminary evidence that retreatment with the Sight Sciences TearCare System is a safe and effective treatment...

read more +
Sight Sciences Initiates U.S. Pivotal Trial of the TearCare® System for the Treatment of Dry Eye Disease

Sight Sciences, Inc., a growth-stage medical device company transforming the two fastest growing segments in ophthalmology and optometry, glaucoma and dry eye treatment, today announced the initiation of the OLYMPIA...

read more +